KLK3 and posterior cortical atrophy: LuCaP23.1 represents a relevant model for studying therapeutic interventions in a preclinical setting because it retains major clinical hallmarks of human PCa, including heterogeneous growth, prostate specific antigen (PSA) production, androgen-responsiveness, and resistance to castration [18].